Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076594 | 1.00 | LMNA (0.44) | LMNAKDM4ETSHRDPP4GAA | |
| SCHEMBL3533488 | 0.98 | TSHR (0.45) | LMNAKDM4ETSHRDPP4GAA | |
| SCHEMBL5177302 | 0.95 | DPP4 (0.46) | LMNAKDM4ETSHRDPP4 | |
| SCHEMBL3540440 | 0.95 | DPP4 (0.46) | LMNAKDM4ETSHRDPP4 | |
| SCHEMBL4725342 | 0.91 | HPGD (0.41) | TSHR | |
| SCHEMBL28381807 | 0.89 | CYP2D6 (0.41) | LMNAKDM4ETSHRDPP4 | |
| SCHEMBL4777579 | 0.88 | HSD17B2 (0.43) | LMNAKDM4E | |
| SCHEMBL3517602 | 0.85 | L3MBTL3 (0.41) | — | |
| SCHEMBL3517661 | 0.85 | L3MBTL3 (0.41) | — | |
| SCHEMBL3515137 | 0.85 | SLC6A3 (0.42) | LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234424-A1 | DERIVATIVES OF N-PHENYL(PIPERIDINE-2-YL) METHYL BENZAMIDE PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | disclosed |
| CN-100482646-C | N- [ phenyl (piperidin-2-yl) methyl ] benzamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2009-04-29 | — | — | CN | disclosed |
| US-7326722-B2 | N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
| EP-1527048-B1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SANOFI-AVENTIS (FR) | 2007-08-23 | — | — | US | disclosed |
| US-20070155789-A1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2007-07-05 | — | — | US | disclosed |
| EP-1499589-B1 | DERIVATIVES OF N-PHENYL(PIPERIDIN-2-YL)METHYL BENZAMIDE, THE PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | EP | disclosed |
| US-7205319-B2 | exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2 | SANOFI-AVENTIS (FR) | 2007-04-17 | — | — | US | disclosed |
| CN-1662497-A | N- [ phenyl (piperidin-2-yl) methyl ] benzamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2005-08-31 | — | — | CN | disclosed |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2005-07-21 | — | — | US | disclosed |
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SLC1A2, SLC1A1, SLC1A5 | LMNA 2684/4885KDM4E 2031/4885TSHR 2785/4885 |
| US-20100234424-A1 | DERIVATIVES OF N-PHENYL(PIPERIDINE-2-YL) METHYL BENZAMIDE PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME IN THERAPEUTICS | SNCA, GABRE, CHRNA5 | LMNA 503/4885KDM4E 294/4885TSHR 1756/4885 |
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | HDAC6, NAT1, ARG2 | LMNA 1988/4885KDM4E 414/4885TSHR 663/4885 |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | NPR3, NR4A3, PRMT3 | LMNA 2775/4885KDM4E 1061/4885TSHR 50/4885 |
| US-20070155789-A1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | HDAC6, NAT1, ARG2 | LMNA 1988/4885KDM4E 414/4885TSHR 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.